Research record
Belvarafenib + cobimetinib ± nivolumab
A distinct NRAS-mutant melanoma clinical-trial strategy involving RAF/MEK and sometimes PD-1 therapy. It should not be confused with tunlametinib.
What this is
A distinct NRAS-mutant melanoma clinical-trial strategy involving RAF/MEK and sometimes PD-1 therapy. It should not be confused with tunlametinib.
Why it may come up
- NRAS-mutant melanoma that has spread or cannot be removed easily
- after anti-PD-1/PD-L1 therapy
What not to assume
- Do not merge belvarafenib evidence into tunlametinib claims.
At a glance
Belvarafenib + cobimetinib ± nivolumab
- Type
- Targeted therapy
- Mutation result
- NRAS
- Where
- US, Global
- Evidence status
- In clinical trials
- Last checked
- 2026-05-20
What we know
- NCI trial listing describes belvarafenib alone or with cobimetinib or cobimetinib plus nivolumab after anti-PD-1/PD-L1 therapy.
- This is a sourced MEK/RAF/PD-1-related trial lead for NRAS melanoma.
What is unclear
- It does not validate tunlametinib plus nivolumab.
Questions to ask
- Is the trial drug belvarafenib rather than tunlametinib?
- Does the trial require prior anti-PD-1/PD-L1 therapy?
- Which arm includes nivolumab, if any?
Timeline
- trial2021: Belvarafenib/cobimetinib/nivolumab trial record
Sourced lookalike NRAS trial lead; not tunlametinib.
Related trial leads
NCT04835805
Belvarafenib alone or with cobimetinib or cobimetinib plus nivolumab in NRAS-mutant advanced melanoma
A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.